PMEL and melanoma: Direct intradermal administration of protamine-stabilized mRNA encoding for melanoma antigens (Melan-A, Tyrosinase, gp100, MAGE-A1, MAGE-A3, Survivin) to 21 metastatic melanoma patients [42] was well-tolerated, inducing no adverse events of grade 3 or higher.